Navigation Links
MIT engineers design new nanoparticle that could lead to vaccines for HIV, malaria, other diseases
Date:2/22/2011

CAMBRIDGE, Mass.- MIT engineers have designed a new type of nanoparticle that could safely and effectively deliver vaccines for diseases such as HIV and malaria.

The new particles, described in the Feb. 20 issue of Nature Materials, consist of concentric fatty spheres that can carry synthetic versions of proteins normally produced by viruses. These synthetic particles elicit a strong immune response comparable to that produced by live virus vaccines but should be much safer, says Darrell Irvine, author of the paper and an associate professor of materials science and engineering and biological engineering.

Such particles could help scientists develop vaccines against cancer as well as infectious diseases. In collaboration with scientists at the Walter Reed Army Institute of Research, Irvine and his students are now testing the nanoparticles' ability to deliver an experimental malaria vaccine in mice.

Vaccines protect the body by exposing it to an infectious agent that primes the immune system to respond quickly when it encounters the pathogen again. In many cases, such as with the polio and smallpox vaccines, a dead or disabled form of the virus is used. Other vaccines, such as the diphtheria vaccine, consist of a synthetic version of a protein or other molecule normally made by the pathogen.

When designing a vaccine, scientists try to provoke at least one of the human body's two major players in the immune response: T cells, which attack body cells that have been infected with a pathogen; or B cells, which secrete antibodies that target viruses or bacteria present in the blood and other body fluids.

For diseases in which the pathogen tends to stay inside cells, such as HIV, a strong response from a type of T cell known as "killer" T cell is required. The best way to provoke these cells into action is to use a killed or disabled virus, but that cannot be done with HIV because it's difficult to render the virus harmless.

To get around the danger of using live viruses, scientists are working on synthetic vaccines for HIV and other viral infections such as hepatitis B. However, these vaccines, while safer, do not elicit a very strong T cell response. Recently, scientists have tried encasing the vaccines in fatty droplets called liposomes, which could help promote T cell responses by packaging the protein in a virus-like particle. However, these liposomes have poor stability in blood and body fluids.

Irvine, who is a member of MIT's David H. Koch Institute for Integrative Cancer Research, decided to build on the liposome approach by packaging many of the droplets together in concentric spheres. Once the liposomes are fused together, adjacent liposome walls are chemically "stapled" to each other, making the structure more stable and less likely to break down too quickly following injection. However, once the nanoparticles are absorbed by a cell, they degrade quickly, releasing the vaccine and provoking a T cell response.

In tests with mice, Irvine and his colleagues used the nanoparticles to deliver a protein called ovalbumin, an egg-white protein commonly used in immunology studies because biochemical tools are available to track the immune response to this molecule. They found that three immunizations of low doses of the vaccine produced a strong T cell response after immunization, up to 30 percent of all killer T cells in the mice were specific to the vaccine protein.

That is one of the strongest T cell responses generated by a protein vaccine, and comparable to strong viral vaccines, but without the safety concerns of live viruses, says Irvine. Importantly, the particles also elicit a strong antibody response.

In addition to the malaria studies with scientists at Walter Reed, Irvine is also working on developing the nanoparticles to deliver cancer vaccines and HIV vaccines. Translation of this approach to HIV is being done in collaboration with colleagues at the Ragon Institute of MIT, Harvard and Massachusetts General Hospital. The institute, which funded this study along with the Gates Foundation, Department of Defense and National Institutes of Health, was established in 2009 with the goal of developing an HIV vaccine.


'/>"/>

Contact: Caroline McCall
cmccall5@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Tissue engineers create a new way to assemble artificial tissues
2. Engineers turn noise into vision
3. Nanoscale stealth probe slides into cell walls seamlessly, say Stanford engineers
4. Artists, Product Designers, Printing Gurus, Game Developers, Manufacturing Engineers Will Converge at RAPID 2010/3D IMAGING Conference/Expo, May 18-20 in LA
5. Quest for designer bacteria uncovers a Spy
6. Biodesign hosts international consortium on screening for lung cancer
7. Next-generation hospital design can improve health -- and save money
8. Indoor plant intervention: New answers for health care design?
9. Structure of key molecule in immune system provides clues for designing drugs
10. Better Helmet Design Might Lower Soldiers Risk for Brain Injury
11. UM researchers are studying child-mother interactions to design robots with social skills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... The Radiology ... Quest Awards . The annual awards, now in their 12th year, are among the ... the winners. , In 2016, the awards were retooled to recognize achievements in both ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred ... 2017. This sacred and spiritual journey during the Summer Solstice will also ...
(Date:3/24/2017)... ... 2017 , ... The law firm of Enea, Scanlan & Sirignano, LLP, ... resident Lauren C. Enea has joined the firm as an associate attorney. Ms. Enea, ... in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha ...
(Date:3/24/2017)... ... 2017 , ... “Finding Christ Through Social Media: Year One ... the writer’s path toward true communion with God. “Finding Christ Through Social Media: ... creation of published author Lea Michelle Johnson, a follower of Christ, wife and ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... In 2016 ... now estimates that there could be four million Zika-related cases in the Americas within ... with numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... , March 24, 2017 Today ... Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. ... Inc. (NASDAQ: SSH ). These companies are part ... prior gains on Thursday, March 23 rd , 2017, with ... while shares of health care companies in the S&P 500 ...
Breaking Medicine Technology: